XORTX Therapeutics (XORTX Therapeutics) Price-to-Owner-Earnings : (As of Apr. 29, 2024)

View and export this data going back to 2018. Start your Free Trial

What is XORTX Therapeutics Price-to-Owner-Earnings?

As of today (2024-04-29), XORTX Therapeutics's share price is $2.645. XORTX Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.

The historical rank and industry rank for XORTX Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

During the past 8 years, the highest Price-to-Owner-Earnings of XORTX Therapeutics was 5.73. The lowest was 0.00. And the median was 0.00.

XRTX's Price-to-Owner-Earnings is not ranked ^*
in the Biotechnology industry.
Industry Median: 32.12
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-29), XORTX Therapeutics's share price is $2.645. XORTX Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.62. Therefore, XORTX Therapeutics's PE Ratio for today is At Loss.

As of today (2024-04-29), XORTX Therapeutics's share price is $2.645. XORTX Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-3.83. Therefore, XORTX Therapeutics's PE Ratio without NRI for today is At Loss.

During the past 8 years, XORTX Therapeutics's highest PE Ratio without NRI was 2.92. The lowest was 0.00. And the median was 0.00.

XORTX Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for XORTX Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Price-to-Owner-Earnings Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Owner-Earnings

Get a 7-Day Free Trial

XORTX Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Price-to-Owner-Earnings	Get a 7-Day Free Trial															5.82	-	-	-	-

Competitive Comparison of XORTX Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, XORTX Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XORTX Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Price-to-Owner-Earnings falls into.

XORTX Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

XORTX Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings	=	Share Price	/	Owner Earnings per Share (TTM)
	=	2.645	/	-3.65
	=

XORTX Therapeutics (NAS:XRTX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.

XORTX Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (XORTX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Price-to-Owner-Earnings

Comparable Companies

Traded in Other Exchanges

ANUA:Germany XRTX:Canada

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.